Prime Minister Justin Trudeau says that an agreement has been reached with all provinces and territories to top up the wages of some essential front-line workers including those in long-term care facilities where COVID-19 has spread among both residents and staff, with deadly impact. This comes as the military deployment to long-term care homes is being expanded.

There are many challenges to developing a vaccine that will be successful against COVID-19.eamesBot / Shutterstock

Wayne Koff is one of the world’s experts on vaccine development, the president and CEO of the Human Vaccines Project. He possesses a deep understanding of the opportunities and challenges along the road to a safe and effective vaccine against COVID-19. He has won prestigious awards, published dozens of scientific papers, held major positions in academia, government, industry, and nonprofit organizations. But Koff, 67, has never produced a successful vaccine.

“I have been an abject failure,” he says. He smiles with a charming, self-deprecating sense of humor. “That’s what the message is.”

The real reason for Koff’s lack of success is that he spent most of his career searching for a vaccine against HIV, the virus that causes AIDS. It remains, as he and many others put it, “the perfect storm” of a viral infection resistant to a vaccine development. Almost 40 years after doctors first recognized the disease in five men in Los Angeles—and 70 million people have been infected worldwide—there are no adequate animal models. Neutralizing antibodies, the backbone of many vaccines, do not stop it, and most importantly, HIV begins its assault on the body by attacking CD4 T cells, which serve as the command center of much of the immune system.

As for COVID-19, “We’re all hoping this one is going to be easier,” says Koff, a slight, bearded man with thick, curly salt-and-pepper hair. “There are research issues that still have to be addressed on a COVID vaccine. But they are a lot more straightforward than what we were dealing with in HIV.”

Let’s say we have a vaccine in 18 months. How do you make 1 billion doses or 4 billion doses or whatever it’s going to take to immunize everybody?

Koff and others started the Human Vaccines Project in 2016, modeled on the Human Genome Project. The project works with industry and academia to study the human immune system and develop vaccines, incorporating every modern-day tool, including artificial intelligence, computational biology, and big data sets. Today it is partnered with the Harvard T.H. Chan School of Public Health.

With COVID-19, Koff says, scientists “know the target is the spike protein binding site.” This is where the proteins sticking out from the virus attach to the cells in the human respiratory system. “If you can elicit antibodies against those proteins, they should be neutralizing.” He puts a strong emphasis on should. To prove antibodies will prevent infection, scientists must watch a population of people who’ve been infected for months or longer. It’s a good bet, based on similar viruses, that antibodies will appear and protect—although no one right now can predict how long and how well.

Depending on which count you use, more than 70 companies, universities, and other institutions are offering candidate vaccines. Koff says the real number of companies is lower. During the AIDS crisis, he says, “a lot of people claimed they had an experimental HIV vaccine in development. Some of those were a one-person lab who had created a paper company to attract investors.”

But even with a lower number, almost everyone involved in the search for a vaccine agrees that several different approaches from different research organizations need to proceed in parallel. The world does not have the time to bet on one horse. The race will be neither simple nor cheap.

“The probability of success, depending on whose metric is used in vaccines, is somewhere between 6 and 10 percent of candidate vaccines that make it from the animal model through licensure,” Koff says. “That process costs $1 billion or more. So you can do the math.”

Koff sees big potential problems at the outset. “In the best of all worlds, let’s say we have a vaccine in 18 months. Who knows where the epidemic is going to be then and what its impact is going to be? How do you make 1 billion doses or 4 billion doses or whatever it’s going to take to immunize everybody? Will we need one dose or two or three? These are issues people just haven’t faced before.”

COVID-19 also presents some unique dangers for vaccine safety. Based on how the virus behaves when it infects some people, there’s a chance a vaccine could dangerously overstimulate the immune system, a reaction called immune enhancement. “I’m hoping it’s more theoretical than real,” Koff says. “But that has to be addressed and it may slow down the entire process.” To ensure safety, he says, “It may mean we have to test the vaccine in a larger number of people. It’s one thing to do a 50-person trial in healthy adults as a safety signal. It’s another thing to run a trial of 4,000 or 5000 or more individuals.”

The world does not have the time to bet on one horse. The race will be neither simple nor cheap.

A virus also sometimes causes mysterious, potentially deadly blood clots. This means an experimental vaccine could hypothetically induce the same damage. “This is a bad bug,” Koff says. “We’re just starting to understand that pathogenesis.”

A big question is who should be the first volunteers for widespread vaccine testing. “Who are the high-risk groups?” asks Koff. “Is it nursing-home residents and staff, health-care workers and people on the front lines, or people someplace else like grocery stores? We must also make sure a vaccine is effective for the elderly and people in the developing world.”

Many vaccines work well in young and healthy people but not in older adults because immunity declines with age. Influenza vaccine is a prime example. Rotavirus vaccine, which protects against the deadliest killer—diarrheal disease in children—works better in the developed world. In the developing world, the virus often circulates year-round. Infants get antibodies from breast milk but not enough to prevent disease. Worse, those antibodies can make the vaccine less effective.

Another hypothetical obstacle is that a mutation in the COVID-19 virus could render a vaccine designed today less effective in the future. While the virus mutates frequently, so far there has been little change in the critical part of the spike that binds to human cells.

Of course, neither Koff nor all the others working for a COVID-19 vaccine focus solely on the potential obstacles. At one time, all vaccines against viruses either killed viruses, such as the Salk polio vaccine, or rendered them harmless, such as the Sabin polio vaccine. Now there is a multiplicity of ways to stimulate an immune response to prevent infection or reduce the consequences. These include genetically engineered protein subunits (peptides) or virus-like particles. Such approaches have led to successful vaccines against hepatitis B and human papilloma virus, which causes cervical cancer. Researchers now use “vectors”—harmless viruses attached to the protein subunits and virus particles to transmit them into the body. There are also many new adjuvants, chemicals that boost immune response to a vaccine.

Newer platforms include direct injection of messenger-RNA. M-RNA is the chemical used to translate the information in DNA into proteins in all cells. The Moderna Company, which received a $483 million grant from the U.S. government, and has begun early clinical trials, uses m-RNA to try to make the body produce proteins to protect against the COVID-19 virus. INOVIO Pharmaceuticals uses pieces of DNA called plasmids to achieve the same objective. It has also begun phase 1 studies.

“There are about eight platforms, and it would be good to see a couple vaccines in each of those advance,” Koff says. Predicting which of these most likely to succeed or fail he says would be “simply foolish.”

Many groups, including the Human Vaccines Initiative, are plotting routes to test any possible vaccine more quickly than tradition dictates with an “adaptive trial design.” Usually trials begin with a phase 1 study of some 50 healthy people to search for any immediate signs of toxicity, then moves onto about 200 people in a phase 2, still looking for hazards and a signal of immunity, and then to phase 3 in thousands of people. But the plan here is to start phases 2 and 3 even before its predecessors are finished, and keep recruiting additional volunteers so long as no danger signals arise.

Good animal models are appearing almost daily. Macaque monkeys, hamsters, and genetically engineered mice have all been infected in the laboratory and could determine whether potential vaccines exhibit various types of immunity. Members of Congress from both sides of the aisle have suggested that healthy human volunteers should be allowed to agree to be test subjects, allowing themselves to be infected. Stanley Plotkin, a vaccine researcher at the University of Pennsylvania, was among the first to suggest the idea.

Arthur Caplan, a bioethicist at New York University, says that “deliberately causing disease in humans is normally abhorrent.” But COVID-19 is anything but a normal circumstance. In this case, Caplan says, “asking volunteers to take risks without pressure or coercion is not exploitation but benefitting from altruism.” At least 1,500 people have already volunteered to be such human guinea pigs, although none of the experimental vaccines is far enough along to try such challenging experiments.

Koff says the key to a successful vaccine is a cooperative effort. “It’s going to take a whole different way of thinking to move this onto the expedited train,” he says. “The old dog-eat-dog, ‘I’m going to beat you to the end of the game,’ isn’t going to help us with this.” Seth Berkley, who worked with Koff at the International AIDS Vaccine Initiative, and now heads GAVI, an international vaccine organization, agrees that a COVID-19 vaccine needs a Manhattan Project approach. “An initiative of this scale won’t be easy,” Berkley says. “Extraordinary sharing of information and resources will be critical, including data on the virus, the various vaccine candidates, vaccine adjuvants, cell lines, and manufacturing advances.”

Koff has no regrets about spending so many years on an AIDS vaccine without results. He learned a great deal, he says, which he’s putting to work in the COVID-19 crisis. “The reason COVID-19 vaccines should be a lot easier is because most of the platforms, the novel approaches, and the clinical infrastructure for the testing of vaccines, came out of HIV.” He pauses. “We’re far better prepared.”

Robert Bazell is an adjunct professor of molecular, cellular, and developmental biology at Yale. For 38 years, he was chief science correspondent for NBC News.

The Ontario government paved the way Friday, easing restrictions on pro sports teams by allowing them to open their training facilities providing they follow their league's "established health and safety protocols" in response to COVID-19.

Team training facilities have been closed, other than for approved rehab, since the league suspended play March 12 due to the global pandemic.

The team says that after working closely with the local government, infectious disease experts and public health authorities, players will be allowed to access the OVO Athletic Centre starting next week.

Mayim Bialik, Debra Messing, Finn Wolfhard and many others joined

Hit musical series ran for six seasons from 2010 to 2015

Mario Lopez, Elizabeth Berkley and Mark-Paul Gosselaar are among the show's returning cast members

The 'X-Men' actor donated £275,000 to the 'Masks for NHS Heroes' campaign

The heavily tattooed comedian was spotlighted in a segment on the BBC current affairs programme because of his volunteering work

New comedy special coming on 5 May

The BBC's charity event will star Lenny Henry, Catherine Tate and many more famous faces

Charity event sketch also saw Reverend Geraldine make a 'chocolate bra' and speak of her friends on the Dibley Parish Council

There's a lot to love about the fantastical and immaculately choreographed violence, but Sky's buzzy crime thriller otherwise tends to wallow in giggle-inducing melodrama

Government has pledged to match the total raised from the three-hour telethon

Adaptation of Sally Rooney's love story stars Paul Mescal and Daisy Edgar-Jones

'I think he did a great job'

News comes as Ellen DeGeneres allegedly leaves 'distressed' staff members in the dark

The show is due to return in September

Captain Moore was presented the award by his grandchildren

The Nigerian musician was a restless creator who embraced the physicality of drumming and innovated until the end

• Tony Allen’s 10 best tracks
• News report: Afrobeat co-founder Tony Allen dies aged 79

Few musicians can claim to have invented a revolutionary rhythm, but then few are quite like the late Afrobeat pioneer Tony Allen. Brian Eno called him “the greatest drummer that ever lived”, citing his style alongside James Brown’s funk breakbeat and the constant pulse of German band Neu! as the “three great beats of the 1970s”. Allen’s swirl of jazz, Yoruba and highlife was unlike anything the world had ever heard: a full-body polyrhythmic workout that would give most drummers sore wrists just thinking of it.

Allen came to prominence in Lagos alongside Fela Kuti. He started drumming in the late 50s while working at a radio station, looking to jazz icons such as Art Blakey and Max Roach for inspiration as he taught himself to play. In 1964 he met Kuti and they spent the next half-decade fine-tuning their fusion of west African party music and American funk and jazz, in the bands Koola Lobitos and, by 1969, Africa ’70. While Kuti, who died in 1997, is more well-known than his musical soulmate, he said that “without Tony Allen there would be no Afrobeat”.

The chief prosecutor will seek capture of Jordan Goudreau as well as two US-based advisers to opposition leader Juan Guaidó

• How the plot to invade Venezuela fell apart

Venezuela’s chief prosecutor has ordered the arrest of a former Green Beret and two opposition figures living in the United States for their purported role in a botched operation aimed at removing Nicolás Maduro from power.

Tarek William Saab said Venezuela will seek the capture of Jordan Goudreau, a military veteran who has claimed responsibility for the attack, as well as Juan José Rendón and Sergio Vergara, two US-based advisers to the opposition leader Juan Guaidó.

As businesses in the United States slowly begin reopening, researchers in Pennsylvania are turning to dogs to help them fend off a second wave of COVID-19.

Tomlinson appears in a bathtub wearing nothing but a shower cap in the cover video

The 99-year-old is walking the length of his garden 100 times to raise funds

The couple met while the judge was on the Strictly tour

Star-studded stories from the silver screen

Fancy an Olympic torch? Or perhaps a four poster bed? You've come to the right place...

Holden is raising money for the NHS through the release of her first single

Coronavirus: the symptoms

Stuck With U will be released later this month

Tributes have poured in for Scrubs actor Sam Lloyd, who has died at the age of 56.

The former glamour model recently recovered from coronavirus

The Body Coach said he feels "eternally grateful" for the health service

Alesha Dixon's daughter also makes an appearance

The singer also suggested women aren't encouraged to get into music production from an early age

Coronavirus: The Symptoms

From Norwegian fjords to the sweeping coastal views of Montenegro, it's time to daydream about these lush European journeys

All profits from the £20 bag will go directly to NHS Charities Together, a not-for-profit conglomeration of 250 good causes attempting to raise £1 million every day for hospitals

A round of applause for our carers

Shopping app Kindred and #ClapForOurCarers have launched the cutest t-shirt... and the celebs are loving it

The retro runner has made (another) comeback

Red and yellow and pink and blue, which one is most you?

'I hoped to raise £5k with Run For Heroes ... now the total is over £5m'

Lockdown in London has turned some of us into pluviophiles

Going live on social media? Add a donation sticker while you're at it

The Muay Thai boxer has been training throughout Ramadan for years, here she shares her expert tips

The app now counts 1.6 million users

These snazzy steals are guaranteed smile-inducers